SCHEMBL16235619

SCHEMBL16235619

N#Cc1cccc(S(=O)(=O)Nc2nnc(Cl)cc2O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLO1 Q04760 1/20 0.48
▸ SLC40A1 Q9NP59 1/20 0.48
▸ PGR P06401 1/20 0.47
▸ PGAM1 P18669 1/20 0.46
▸ ACLY P53396 3/20 0.45
▸ PTGES2 Q9H7Z7 1/20 0.45
▸ CRBN Q96SW2 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44
▸ CCR1 P32246 1/20 0.44
▸ CCR2 P41597 1/20 0.44
▸ CCR4 P51679 1/20 0.44
▸ HSD17B1 P14061 2/20 0.43
▸ HSD17B2 P37059 2/20 0.43
▸ PIK3CD O00329 1/20 0.43
▸ KAT6A Q92794 1/20 0.43
▸ HSPD1 P10809 1/20 0.43
▸ PTPN2 P17706 1/20 0.43
▸ PTPN1 P18031 1/20 0.43
▸ PTPN5 P54829 1/20 0.43
▸ HSPE1 P61604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16235422 0.82 ACLY (0.56) GLO1SLC40A1PGRACLYCRBN
SCHEMBL16235532 0.81 SLC22A12 (0.41) ACLYPTGES2
SCHEMBL16235351 0.81 ACLY (0.42) ACLYHSD17B2
SCHEMBL16235419 0.80 KDM4E (0.56) PGRMAPT
SCHEMBL16235159 0.78 PTGES2 (0.47) PGRACLYPTGES2CCR2CCR4
SCHEMBL16235417 0.77 SLC40A1 (0.51) SLC40A1PGRACLYHSPD1PTPN2
SCHEMBL16235024 0.76 SLC40A1 (0.50) SLC40A1PGAM1PTGES2KAT6A
SCHEMBL16235614 0.76 S100A9 (0.48) ACLYCCR4
SCHEMBL16235445 0.75 S100A9 (0.54) PTGES2MAPT
SCHEMBL15180084 0.75 RXFP1 (0.67) GLO1SLC40A1PGRACLYRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-11-13 — — US claimed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 — — US claimed
US-9873687-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-01-23 — — US claimed
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-04-28 — — US claimed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 — — EP claimed
EP-2925743-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS Active Biotech AB (SE) 2015-10-07 — — EP claimed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 — — WO claimed
US-20220378763-A1 COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM CALPROTECT AB (SE) 2022-12-01 — — US disclosed
WO-2020260692-A1 COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM CALPROTECT AB (SE) 2020-12-30 — — WO disclosed
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-11-13 — — US disclosed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 — — US disclosed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 — — US disclosed
US-9873687-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-01-23 — — US disclosed
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-04-28 — — US disclosed
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-04-28 — — US disclosed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 — — EP disclosed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 — — EP disclosed
EP-2925743-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS Active Biotech AB (SE) 2015-10-07 — — EP disclosed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 — — WO disclosed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220378763-A1 COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM TNNT2, TNNI3, HMGB1 GLO1 2764/4885SLC40A1 3310/4885PGR 3837/4885
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors S100A9, S100B, S100A10 GLO1 2255/4885SLC40A1 370/4885PGR 2888/4885
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100B, S100A10 GLO1 2255/4885SLC40A1 370/4885PGR 2888/4885
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100A4, S100B GLO1 1549/4885SLC40A1 751/4885PGR 3174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback